Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Applied Dna Scns
(NQ:
APDN
)
1.685
+0.405 (+31.64%)
Streaming Delayed Price
Updated: 10:04 AM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Applied Dna Scns
< Previous
1
2
3
4
5
Next >
Applied DNA Launches Mpox Clade I and Clade II Testing Service
Today 5:00 EDT
Via
ACCESSWIRE
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
September 04, 2024
Via
ACCESSWIRE
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 23, 2024
Via
ACCESSWIRE
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 19, 2024
Via
ACCESSWIRE
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
August 08, 2024
Via
ACCESSWIRE
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
June 18, 2024
Via
ACCESSWIRE
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform
June 05, 2024
Via
ACCESSWIRE
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
April 25, 2024
Via
ACCESSWIRE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
February 08, 2024
Via
ACCESSWIRE
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
August 07, 2024
Via
ACCESSWIRE
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29, 2024
Via
ACCESSWIRE
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
July 29, 2024
Via
ACCESSWIRE
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
July 25, 2024
Via
ACCESSWIRE
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
July 18, 2024
Via
ACCESSWIRE
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
December 07, 2023
Via
ACCESSWIRE
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
June 20, 2024
Via
ACCESSWIRE
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13, 2024
Via
ACCESSWIRE
Applied DNA Announces Pricing of $12 Million Public Offering
May 28, 2024
Via
ACCESSWIRE
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13, 2024
Via
ACCESSWIRE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
May 10, 2024
Via
ACCESSWIRE
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 10, 2024
Via
ACCESSWIRE
Applied DNA Announces 1-For-20 Reverse Stock Split
April 22, 2024
Via
ACCESSWIRE
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
April 09, 2024
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.
Via
MarketBeat
Topics
Cannabis
Exposures
Cannabis
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
March 18, 2024
Via
ACCESSWIRE
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
March 14, 2024
Via
ACCESSWIRE
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
February 05, 2024
Via
ACCESSWIRE
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 02, 2024
Via
ACCESSWIRE
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 31, 2024
Via
ACCESSWIRE
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
December 14, 2023
Via
ACCESSWIRE
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
December 05, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.